GDC-0623   Click here for help

GtoPdb Ligand ID: 9909

Synonyms: G-868 | GDC 0623 | GDC0623 | RG-7421 | RG7421
PDB Ligand
Compound class: Synthetic organic
Comment: GDC-0623 (RG-7420) is an ATP-uncompetitive MEK1 inhibitor that was developed by Genentech for anti-cancer potential [3]. The structure of GDC-0623 was disclosed for the first time in 'Supplementary Figure 1a' provided with Hatzivassiliou et al. (2013) [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 87.89
Molecular weight 456.01
XLogP 4.52
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCCONC(=O)c1ccc2n(c1Nc1ccc(cc1F)I)cnc2
Isomeric SMILES OCCONC(=O)c1ccc2n(c1Nc1ccc(cc1F)I)cnc2
InChI InChI=1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)
InChI Key RFWVETIZUQEJEF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A single Phase 1 safety, tolerability and PK clinical trial of GDC-0623 was completed in patients with advanced/metastatic solid tumours (NCT01106599), but the lack of further activity suggests that development of this candidate has been discontinued.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The mitogen-activated protein kinase (MAPK) pathway (the Ras/Raf/MEK/ERK signaling cascade) is one of the most important pathways involved in cell proliferation and differentiation, and abberant pathway activation driven by K-Ras or B-Raf mutations in tumours is common. Hence, drug companies have long been developing inhibitors of components of the MAPK pathway as cancer chemotherapeutics [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01106599 A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1 Interventional Genentech, Inc.